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Background: Chronic rhinosinusitis with nasal polyposis is common in patients with cystic ﬁbrosis (CF). There are still many open questions
regarding factors related to this condition. Furthermore, the prevalence of nasal polyposis and its implications for the outcomes in lung transplant
recipients with cystic ﬁbrosis are unknown.
Methods: All CF patients who underwent lung transplantation at our centre between November 1992 and December 2009 were included. Nasal
polyp status was determined endoscopically at time sinus surgery and its relationships to gender, age at lung transplantation, Liou raw score, body
mass index, FEV1%predicted, diabetes mellitus, pre-transplant pseudomonas colonisation of the sinuses and the lungs, pre-transplant corticosteroid
use and type of mutation of the CFTR gene were analysed. The post-transplant survival times and the incidence of bronchiolitis obliterans
syndrome in patients with or without nasal polyposis were compared.
Results: Nasal polyps were found in 19% (17 patients) of the 89 lung transplant recipients, whose data was available for statistical analysis. None
of the factors analysed was related to the nasal polyp status. The post-transplant survival times and the incidence of bronchiolitis obliterans
syndrome did not signiﬁcantly differ between patients with or without nasal polyposis.
Conclusions: CF-related nasal polyposis occurs in a relevant fraction of lung transplant recipients. A speciﬁc effect of nasal polyposis on post-
transplant outcome could not be conﬁrmed. Nevertheless, there was a trend to NP recurrence in patients with post‐transplant sinonasal
pseudomonas colonisation and is a tendency of less chronic rejection in CF patients with nasal polyps.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Lung transplantation; Chronic rhinosinusitis; Nasal polyposis; Survival; Bronchiolitis obliterans syndrome1. Introduction
Chronic rhinosinusitis with nasal polyposis (NP) is common
in patients with cystic fibrosis (CF), with an estimated prevalence
of 6–48% [1–7]. Despite its frequency, there are still many open
questions regarding the origin of polyp growth. Some argue that
the CF genotype may play a major role [1,8–10], and chronic
colonisation with Pseudomonas aeruginosa might be a co-factor
for NP [11].⁎ Corresponding author at: Division of Pulmonary Medicine, University
Hospital Zurich, Raemistrasse 100, 8091 Zürich, Switzerland. Tel.: +41 44 255
39 26; fax: +41 44 255 89 97.
E-mail address: mhofer@hispeed.ch (M. Hofer).
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2012.08.013Some studies have suggested that CF patients with NP show
milder lung disease and have better survival rates than patients
without NP [1,5,6,9], whereas others found no relationship
between NP status and the severity of CF [12]. Moreover, the
influence of a potentially specific CF phenotype with NP on
bronchiolitis obliterans syndrome (BOS) and survival after lung
transplantation (LTx) is not known, but might have both
practical and prognostic implications in this group of patients
with terminal CF lung disease.
The aim of this study was to determine the prevalence of NP
in CF patients undergoing lung transplantation, to identify
potential predictors for NP and to examine the survival and
cumulative incidence of BOS of lung transplant recipients with
and without NP.by Elsevier B.V. All rights reserved.
Table 1
Characteristics of CF patients with and without nasal polyps (NP).
With NP Without NP
N, % 17 (19) 72 (81)
Female/male (n, %) 9/8 (53/47) 35/37 (49/51)
Age at LTx (year (95%CI)) 26 (22–30) 27 (25–29)
Body mass index (kg/m2, 95%CI) 16.6 (15.8–17.5) 17.7 (17.0–18.3)
FEV1 (litres, 95%CI) 0.74 (0.65–0.83) 1.09 (0.62–1.55)
FEV1%predicted (%,95%CI) (%,95%CI) 23 (19–26) 26 (25–28)
Survival without LTx at 5 years
(%,95%CI)
31 (24–38) 33 (30–37)
PrePA-nose (n, %) 15 (88) 59 (82)
PrePA-lung (n, %) 15 (88) 55 (76)
PreCS-use (n, %) 4 (24) 23 (33)
dF508 homozygotes (n, %) 9 (53) 40 (56)
CFDM (n, %) 8 (47) 48 (67)
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All CF patients undergoing LTx at our centre between
November 1992 and December 2009 were included in this
study, and the data was collected retrospectively. The lung
transplant recipients were followed until the end of December
2011, representing a minimum follow-up of two years per
patient. The candidates for LTx were carefully selected
following the international guidelines of the ISHLT Pulmonary
Scientific Council [13]. The transplantation type was a
sequential bilateral lung transplantation as described previously
[14].
The standard protocol of immunosuppression (cyclosporine,
azathioprine or mycophenolate mofetil and prednisolone) and
induction therapy (anti-thymocyte globulin or basiliximab) was
followed as described by Speich et al. [15]. On the basis of the
sputum cultures, all patients were treated with a combination of
at least two antibiotics for Pseudomonas aeruginosa (PA) for at
least the first two weeks after LTx [14]. Further prophylactic
therapy included cotrimoxazole, acyclovir/valacyclovir, oral
itraconazole and nebulised amphotericin B. In addition, all
transplant recipients with CF received a nebulised therapy with
Colistin as prophylaxis against infection [14]. Inhalations with
Colistin started immediately after LTx and were continued
lifelong if patients had airway cultures positive for PA.
After the patient recovered from the transplantation, routine
sinus surgery was performed as described previously [16].
Nasal polyp (NP) status was determined using the rigid
endoscope at time of sinus surgery. The surgery consisted of
an endoscopic fronto-spheno-ethmoidectomy as descried else-
where [17,18]. In this procedure, all sinuses are widely opened
and explored no matter how well they are pneumatised [16].
Daily nasal douching with isotonic saline solution was initiated
on the second day after surgery. A potential relapse of NP was
determined at the post-transplant follow-up visits by nasal
endoscopy.
Microbiological sampling was performed with bronchoscopy
and bronchoalveolar lavage (BAL) along with nasal endoscopy
and aspiration of sinus secretions. Bacterial colonisation with PA
was considered significant if bacterial counts were 104 colony-
forming units/ml or more.
The diagnostic criteria for bronchiolitis obliterans syndrome
(BOS) were applied as described elsewhere [19]: BOS 0 was
defined as FEV1 (forced expiratory volume in 1 s) N90% of
baseline and FEF25-75 (mid-expiratory flow rate) N75% of
baseline; BOS 0-p as FEV1: 81 to 90% of baseline and/or
FEF25–75: ≤75% of baseline; BOS 1 as FEV1: 66 to 80%; BOS
2 as FEV1: 51 to 65%; and BOS 3, FEV1: ≤50% of baseline.
Estimated pre-LTx survival was calculated according to Liou et
al. [20].
3. Statistical analysis
Descriptive statistics were used, and the mean and 95%
confidence intervals (95% CI) are reported. Two groups were
defined: Patients with nasal polyps (with NP) and without nasal
polyps (without NP) at time of sinus surgery. Mann–Whitneytests and Fisher's Exact Tests (2×2 tables) were used to
compare these groups, and a p-level b0.05 was considered as
significant (two-tailed).
Survival and BOS following LTx were evaluated using
Kaplan–Meier estimates. The groups with or without NP were
compared with log rank tests. A multivariate analysis for the
development of NP was performed. The following parameters
were evaluated: gender, pre-transplant FEV1, BMI, estimated
survival without LTx, pre-transplant sinonasal and pulmonary
PA colonisation (prePA-nose and prePA-lung), systemic pre-
transplant corticosteroid treatment (preCS-use), pre-transplant
diabetes (CFDM) and dF508 homozygosity. NP relapse rates
and its relation to post-transplant sinonasal and pulmonary PA
colonisation (postPA-nose and postPA-lung) were analysed
using Fisher's Exact Tests (2×2 tables). IBM® SPSS®
Statistics version 19 was used for the statistical analysis.
The institutional review board of the University Hospital
Zurich (Kantonale Ethikkommission Zurich) approved this
retrospective study.
4. Results
Five of the 94 CF patients did not undergo sinus surgery due
to allograft deficiency, multiorgan failure or severe infection/
sepsis and were excluded due to missing information on NP.
The 89 evaluated patients (44 females, 49%) had a mean age of
26.9 years (95%CI 25.2–28.6 years) at LTx, a pre-LTx FEV1
of 1.0 l (0.65–1.40 l) (26% of predicted FEV1 (24–27%)) and
an estimated 5-year survival without LTx of 33% (30–36%)
(Table 1). Seventeen patients (19%) had nasal polyps by rigid
endoscopy.
No difference was found regarding gender, pre-transplant
FEV1 or BMI, estimated survival without LTx, pre-transplant
sinonasal or pulmonary PA colonisation, systemic pre-transplant
corticosteroid treatment, pre-transplant diabetes or the presence
or absence of dF508 homozygosity of the CFTR gene (Table 1).
In the uni- and multivariate analysis none of the investigated
parameters (gender, pre-transplant FEV1, BMI, estimated surviv-
al without LTx, prePA-nose, prePA-lung, preCS-use, CFDM and
type of mutation of the CFTR gene) favoured the development of
NP.
Fig. 1. Survival and freedom of BOS 1 in CF patients with nasal polyps (NP)
and without (w/o NP).
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(71%) of the 17 patients who presented with NP at sinus
surgery. Sinonasal colonisation with PA (postPA-nose) after
LTx and sinus surgery was present in 10 (83%) of the 12
patients with a relapse of NP, which represents a trend towards
NP recurrence in these patients (p=0.083). A statistical
relationship between recurrence of NP and colonisation of the
lung allograft (postPA-lung) could not be observed (Table 2).
Overall, the 1-, 5- and 10-year survival rates were 90.3±3%,
71±5% and 59±6%, respectively. One-, 5- and 10-year
survival rates in patients with NP were 94±6, 77±10% and
61±13% compared with 89±4%, 69±6% and 59±7%,
respectively, in patients without NP (Fig. 1). No significant
difference was found regarding the development of BOS in the
two groups (88±7% of the patients with NP were free from
BOS1 compared with 78±5% in patients without NP).
Nevertheless, there was a tendency towards a lower frequency
of BOS stage 1 in the later post-transplant phase in patients
with NP (Fig. 1).5. Discussion
We report four major findings: 1.) NP was observed in
almost one fifth of the lung transplant recipients with CF;
2.) we could not find predictors for the development of NP in
end-stage CF patients; 3.) there is a trend towards NP recurrence
in patients with sinonasal PA colonisation after LTx and sinus
surgery and 4.) post-transplant survival of patients with NP did
not differ significantly from survival of patients without NP and
cumulative incidence of BOS showed a non-statistically
significant association with NP status.5.1. Prevalence of NP
The prevalence of NP in patients with end-stage CF lung
disease requiring LTx does not seem to differ significantly from
other CF patients [1–7]. Some authors have observed a milder
lung disease in CF patients with NP [1,5,6,9]. If these findings
were true, one would expect a lower prevalence of NP in lung
transplant recipients with CF compared with other groups of CF
patients. On the contrary, the prevalence of NP in our patients
lies within the range of prevalence data reported in the literature
[1–7]. However, a direct control group of CF patients, who did
not require LTx, is not included in our study, given that our
experimental design focused on lung transplant recipients.Table 2
Nasal polyp (NP) recurrence and colonisation with Pseudomonas aeruginosa
(PA) after endoscopic sinus surgery.
NP recurrence
Yes (n, %) No (n, %)
PostPA-nose ⁎ Yes (n, %) 10 (59) 2 (12)
No (n, %) 2 (12) 3 (18)
PostPA-lung Yes (n, %) 7 (41) 1 (6)
No (n, %) 5 (29) 4 (24)
⁎ Fisher's Exact Test p=0.083.Therefore, direct comparisons of NP prevalence in patients with
or without LTx will require additional research.
In our cohort, detection of NP was based on endoscopic
examination. The value of radiologic imaging in the diagnosis
of sinonasal disease of CF patients was discussed in the
literature [21,22]. Whereas CT of the sinuses is able to localise
sinonasal disease and show its extent, it cannot distinguish
between thickened mucosa and infectious material. It was
therefore proposed to use MR imaging to differentiate pus-filled
areas frommucosal thickening without infection. Thereafter, the
pus-filled areas could be selectively eradicated by surgery and
patients might be spared from unnecessary radiation by CT.
Furthermore, patients may be followed by MRI to not to miss
recurrent infection [21,22].
As it was published in earlier studies [16,17], the goal of our
surgical concept of post‐transplant sinus surgery in lung
transplant recipients with CF – together with a meticulous
daily nasal care – is to reduce sinonasal colonisation and to
prevent subsequent lung allograft infections with bacterial
germs. For these purposes, all sinuses have to be widely opened
no matter if they contain infectious fluid retentions or polyp
tissue. To plan and perform this extensive surgical procedure,
preoperative CT examination of the sinuses is crucial [23] and
cannot be replaced by MRI due to its deficit in displaying the
complex osseous structures of the viscerocranium. After having
performed the extensive fronto-spheno-ethmoidectomy, the
patient's sinuses may be examined easily with the rigid
endoscope at the follow-up visits that is why there is no need
for regular radiologic follow-up examinations as long there is
no indication for revision surgery.
5.2. Predictors for nasal polyps and nasal polyp recurrence
None of the investigated factors (gender, age at LTx, Liou
raw score, BMI, FEV1%predicted, CFDM, prePA-nose, prePA-
lung, preCS-use nor the presence or absence of dF508
homozygosity) was predictive for the development of nasal
polyps in our population with end-stage lung disease.
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growth with specific CFTR gene mutations, a relationship to
dF508 homozygosity was not confirmed [1,8–10]. We rather
suggest that NP is a feature of CF, which is sporadically
associated with all degrees of CF severity [4,12].
Furthermore, pre-transplant PA infections were not related
to the development of NP. Kingdom et al. [1] as well as
Henriksson et al. [4] claimed that colonisation with PA is
secondary to the chronic rhinosinusitis associated with NP. In
contrast, Raj et al. [11] hypothesised that NP is secondary to an
atopic inflammatory process against the colonised PA.
Regardless if the CF-related NP is secondary to a chronic
colonisation with PA or if the appearance of PA is a result of
the presence of NP, it is important to assess sinonasal
colonisation with PA and other pathogens before and after
LTx. It is known that chronic bacterial infection with PA leads
to unopposed neutrophil elastase. This correlates with poor
outcome due to bronchiolitis obliterans syndrome (BOS) and
progressive irreversible graft dysfunction [24]. Walter et al.
[25] and recently Mainz et al. [26] demonstrated that lung
allografts became re-infected with the identical genotype of PA
as it was harboured in the explanted lungs. It was hypothesised
that the upper airways act as a reservoir from which bacterial
germs spread to the lower airways. Our own data, published in
2004 [17] and 2012 [16], supports this hypothesis and
underline the importance of post‐transplant sinus surgery
along with a meticulous daily nasal care, which reduces
bacterial colonisation of the lung allograft significantly. Despite
the absence of a statistical relationship of the NP status and the
pre‐transplant colonisation of the sinuses or the lung with PA,
there is a trend towards recurrence of NP in patients who are
colonised with PA after LTx. Regarding this trend, further
studies have to investigate the recurrence of NP according to
the colonisation with CF-relevant bacterial germs and its
influence on post‐transplant outcome.
In our view, several observations suggest that it is unlikely
that an atopic inflammatory process induces NP in CF patients.
First, atopic responses would be characterised by eosinophils in
polyp tissue. In contrast, the inflammatory responses in NP of
CF patients are predominantly neutrophilic [27]. Allergy is
likely secondary and co-exists in CF in one fifth of the patients
[28,29]. It is, however, not possible to determine the prevalence
of co-existing eosinophilic NP in our CF patients by
histological examination due to the fact that several of our
patients received high-dose systemic corticosteroids before
LTx. It is well known that corticosteroids reduce eosinophilic
inflammation in the nasal mucosa and polyps [30,31]. It
therefore can be assumed that the studied NP mainly is
neutrophilic; a reduction of polyps would be expected by the
high-dose systemic corticosteroids in the case of predominantly
eosinophilic polyps.
In our population, we could not find a relationship of
pre-transplant systemic use of corticosteroid and NP. A recent
review of Mainz and Koitschev [27] on the pathogenesis and
management of NP in CF attributed some effect in polyp
shrinkage and symptom relief in cases of limited NP to topical
nasal corticosteroids. However, only one double-blinded,placebo-controlled, randomized study exists on this topic [3]
and the risk of bias in this work remains rather high. Patient's
follow-up was considerably short (6 weeks) and more than half
of the patients did not complete the course. Due to the lack of
evidence in post-transplant NP and in fact that all post-
transplant patients are under a high immunosuppressive
regimen, our treatment concept of post-transplant CF-related
NP does not include the use of topical nasal steroids.
5.3. Post-transplant survival and cumulative incidence of BOS
A potentially specific CF phenotype with increased survival
after LTx might have practical and prognostic implications
regarding the subgroup of CF patients with terminal lung
disease awaiting LTx. Pre-transplant CF patients with NP might
represent such a distinct subgroup with milder pulmonary
disease and better survival [1,5,6,9]. However, we could not
confirm that CF patients with NP had a better survival after
lung transplantation and incidence of BOS did not differ
significantly between patients with and without NP. However,
there was a trend toward a lower prevalence of BOS stage 1 in
the later post-transplant phase. This finding potentially could be
explained by the Th2 polarisation with high IL5- and IgE-
concentrations of CF patients with NP in contrast to CF patients
without NP, who show a Th1 polarisation with high IFN-Υ and
TGF-β [32]. Th1 proinflammatory cytokines like IFN-Υ, TGF-β
and TNF-α are associated with the development of BOS after
LTx [33], while the number of the IL5- and IL10-producing Th2
cells is significantly lower than in stable patients without BOS
[34]. This trend merits further investigation.
6. Conclusions
CF-associated NP was not related to dF508 homozygosity or
other predictors and occurred sporadically in our cohort of CF
lung transplant recipients with a prevalence of 19%. We could
not confirm any relationship of a specific CF phenotype (with
NP) to post-transplant survival. Nevertheless, there was a trend
to NP recurrence in patients with post‐transplant sinonasal PA
colonisation and a tendency of lesser BOS 1 in patients with the
NP phenotype. These trends need to be investigated in further
studies.
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